Advancing DME Treatment Through Clinical Biomarkers and Extended Dosing Therapies This activity is supported by an educational grant from Genentech, a member of the Roche Group.

TIRUNELVELI: Deans of all government medical colleges in Tamil Nadu have been instructed to ensure that doctors maintain at least 75% attendance before granting ...

The Director of Medical Examination (DME) Assam has released the National Eligibility cum Entrance Test or NEET UG 2025 counselling schedule for state quota seats. Candidates who are eligible for ...

MedNet LLC delivers end-to-end Revenue Cycle Management services—including consulting, charge capture, billing, and denials management—with a focus on Durable Medical Equipment (DME) providers ...

This designation in DME follows the RMAT designation granted for 4D-150 in wet AMD, and to our knowledge, 4D-150 is the first investigational medicine to be granted the designation in both ...

DME has entered into a non-disclosure agreement and memorandum of understanding with Sustany Holdings, effective April 27, 2025.

Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when high blood sugar levels damage small blood vessels in the retina, the light-sensitive tissue ...

A real-world analysis showed a link between continuous glucose monitor (CGM) distribution channel and outcomes for patients with diabetes.

DME Assam Grade 3 admit card: The Directorate of Medical Education (DME), Assam, has released the admit cards for the Grade-III (Non-Technical) posts written examination on the official website ...

The Directorate of Medical Education (DME), Assam, has officially released the admit cards for the Grade-III (Non-Technical) posts written examination today, March 21, 2025.

Duravyu at two dose levels met its primary endpoint in the treatment of diabetic macular edema in a phase 2 clinical trial, according to a press release from EyePoint Pharmaceuticals.&ldquo ...

Opthea plans to advance the clinical development of sozinibercept in DME, following the anticipated release of Phase 3 topline data for wet age-related macular degeneration (wet AMD (NASDAQ: AMD ...